Professor with Tenure, Departments of Oncology and Pediatrics, Georgetown University Lombardi Comprehensive Cancer Center Medical Degree: University of Minnesota, Minneapolis, MN Board certified in Pediatrics, Hematology/Oncology Dr. Jeffrey Toretsky has been studying Ewing sarcoma since 1992. He was among the first to identify that Ewing sarcoma cells could be found in the peripheral circulation as minimal residual disease. He has published experience developing antisense oligonucleotides and RNA against EWS-FLI1. His focus is now on developing molecular-based, targeted therapies for childhood cancers, including Ewing sarcoma and osteosarcoma. After identifying a successful therapeutic compound, Dr. Toretsky and his inter-disciplinary team are now optimizing the chemical structure for increased potency prior to moving into preclinical toxicology and ADME studies. A non-toxic compound would then be advanced into human clinical trials, and could have promising effects on a number of other cancer types. Further work in the laboratory is evaluating the multiprotein complexes containing the oncogene EWS-FLI1 for further dissection of oncogenesis. Dr. Toretsky’s recent research into intrinsically disordered proteins as a critical biochemical structure opens the door to creating small molecule probes that would inhibit protein-protein interactions. Dr. Toretsky also leads the Molecular Oncology Program at the Lombard Comprehensive Cancer Center.
Biography Updated on 4 September 2012